Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma

Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes—together with CD73—the hydr...

Full description

Saved in:
Bibliographic Details
Main Authors: Carsten Müller-Tidow, Peter Dreger, Joseph Kauer, Wolfgang Huber, Clara Kolbe, Berit Brinkmann, Sascha Dietrich, Tobias Roider
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e009245.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items